Европейский рынок нейроэндокринных опухолей – тенденции отрасли и прогноз до 2028 года

Настройте свой отчет Настройте свой отчет Купить сейчас Купить сейчас Бесплатный пример отчета Бесплатный пример отчета
Дом Pharmaceutical Europe Neuroendocrine Tumors Market
Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Европейский рынок нейроэндокринных опухолей – тенденции отрасли и прогноз до 2028 года

  • Pharmaceutical
  • Published Report
  • May 2021
  • Europe
  • 350 Pages
  • Количество таблиц: 316
  • Количество рисунков: 48
Купить сейчасКупить сейчас

>Европейский рынок нейроэндокринных опухолей по классификации (функциональная сеть и нефункциональная сеть), местоположению (легкие, поджелудочная железа, желудочно-кишечный тракт (ЖКТ)), степени злокачественности (степень злокачественности 1 (низкодифференцированная опухоль, степень злокачественности 2 (среднедифференцированная опухоль, степень злокачественности 3 (высокодифференцированная опухоль)), типу (диагностика и лечение), способу введения (перорально и парентерально), конечному пользователю (больницы, специализированные клиники, радиационные центры, уход на дому и другие), каналу сбыта (прямой тендер, больничные аптеки, розничные аптеки, интернет-аптеки и другие), стране (Германия, Франция, Великобритания, Венгрия, Италия, Испания, Россия, Польша, Турция, Швейцария, Нидерланды, Бельгия, Австрия, Норвегия, Ирландия, Литва, остальная Европа) Тенденции отрасли и прогноз до 2028 года

Европейский рынок нейроэндокринных опухолей

Анализ рынка и идеи : Европейский рынок нейроэндокринных опухолей

Ожидается, что рынок нейроэндокринных опухолей будет расти в прогнозируемый период с 2021 по 2028 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 10,2% в прогнозируемый период с 2021 по 2028 год и, как ожидается, достигнет 1 153,85 млн долларов США к 2028 году. Рост заболеваемости нейроэндокринными опухолями выступает в качестве драйвера рынка нейроэндокринных опухолей.

Возникновение опухоли происходит, когда ДНК здоровых клеток повреждается, что приводит к неконтролируемому изменению и росту клеток, в результате чего формируется агрегированная масса клеток. Опухоль может быть раковой и доброкачественной. Злокачественная раковая опухоль растет и распространяется на другие части тела, если ее не обнаружить на ранней стадии и не лечить. Доброкачественная опухоль может расти, но не будет распространяться. Доброкачественную опухоль обычно можно удалить с помощью малоинвазивной хирургии, не причиняя большого вреда.

Ожидается, что технологический прогресс в обнаружении нейроэндокринных опухолей будет способствовать росту рынка нейроэндокринных опухолей. Высокие капиталовложения и низкое соотношение выгод и затрат для биомаркеров и орфанных препаратов являются сдерживающим фактором для роста рынка нейроэндокринных опухолей. Новые методы лечения и разработки в лечении посредством прогресса в технологиях ведут к прекрасной возможности для роста рынка нейроэндокринных опухолей. Строгие государственные правила разработки препаратов для нейроэндокринных опухолей выступают в качестве проблемы для роста рынка нейроэндокринных опухолей.

The neuroendocrine tumors market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the neuroendocrine tumors market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

Европейский рынок нейроэндокринных опухолей

Neuroendocrine Tumors Market Scope and Market Size

The neuroendocrine tumors market is segmented on the basis of the classification, site, grade, type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of classification, the neuroendocrine tumors market is segmented into functional net and non-functional net. In 2021 the non-functional net segment is dominating the neuroendocrine tumors market due to ease of identification and diagnosis and use of novel diagnostic method to remove the non-functional net.
  • On the basis of site, the neuroendocrine tumors market is segmented into lung, pancreas and gastrointestinal tract (GI). In 2021 the gastrointestinal tract (GI) segment is dominating the neuroendocrine tumors market due to the increased prevalence of gastric cancer and presence of strong product pipeline are predicted to dominate the market.
  • On the basis of grade, the neuroendocrine tumors market is segmented into grade 1 (low-grade tumor), grade 2 (intermediate-grade tumor) and grade 3 (high-grade tumor). In 2021, the grade 2 (intermediate-grade tumor) segment is dominating the neuroendocrine tumors market since it can be easily cured by therapeutic treatments and rise in grade 2 (intermediate-grade tumor) cases are predicted to dominate the market.
  • On the basis of type, the neuroendocrine tumors market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the neuroendocrine tumors market due to the increased incidence of pancreatic cancer tumor and increased adoption of automated point-of-care diagnosis in the market.
  • On the basis of route of administration, the neuroendocrine tumors market is segmented into oral and parenteral. In 2021, oral segment is expected to dominate the neuroendocrine tumors market due to availability of medication in oral form, greater patients’ compliance and ease of absorption.
  • На основе конечного пользователя рынок нейроэндокринных опухолей сегментируется на больницы , специализированные клиники, центры радиационной терапии, домашнее здравоохранение и т. д. Ожидается, что в 2021 году сегмент больниц будет доминировать на рынке нейроэндокринных опухолей из-за доступности диагностических машин для обнаружения нейроэндокринных опухолей при наличии политик здравоохранения.
  • На основе канала сбыта рынок нейроэндокринных опухолей сегментируется на прямой тендер, больничную аптеку, розничную аптеку, интернет-аптеку и др. Ожидается, что в 2021 году сегмент прямого тендера будет доминировать на рынке нейроэндокринных опухолей из-за роста числа поставщиков на рынке.

Анализ рынка нейроэндокринных опухолей на уровне страны

Проведен анализ рынка нейроэндокринных опухолей и предоставлена ​​информация о размере рынка по стране, классификации, месту, классу, типу, пути введения, конечному пользователю и каналу сбыта, как указано выше.

В отчете о европейском рынке нейроэндокринных опухолей рассматриваются следующие страны: Германия, Франция, Великобритания, Венгрия, Италия, Испания, Россия, Польша, Турция, Швейцария, Нидерланды, Бельгия, Австрия, Норвегия, Ирландия, Литва и остальные страны Европы.

Германия доминирует на европейском рынке нейроэндокринных опухолей из-за роста числа случаев нейроэндокринных опухолей, возросшей потребности в таргетной терапии и увеличения располагаемого дохода.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, замещающие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние каналов продаж.  

Рост государственных инициатив создает новые возможности на рынке нейроэндокринных опухолей 

Рынок нейроэндокринных опухолей также предоставляет вам подробный анализ рынка для каждой страны, рост в определенной отрасли с продажами нейроэндокринных опухолей, влияние прогресса в области нейроэндокринных опухолей и изменения в сценариях регулирования с их поддержкой рынка нейроэндокринных опухолей. Данные доступны за исторический период с 2011 по 2019 год.

Анализ конкурентной среды и доли рынка нейроэндокринных опухолей

Конкурентная среда рынка нейроэндокринных опухолей содержит сведения о конкурентах. Включены сведения о компании, финансах компании, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, производственных площадках и объектах, сильных и слабых сторонах компании, запуске продукта, испытаниях продукта, одобрении продукта, патентах, широте и широте продукта, доминировании приложений, жизненно важной кривой технологий. Приведенные выше данные относятся только к фокусу компании на рынке нейроэндокринных опухолей.

Компании, охваченные отчетом о рынке нейроэндокринных опухолей, включают F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (дочерняя компания Novartis AG), Merck Sharp & Dohme Corp., дочерняя компания Merck & Co., Inc., Bionano Genomics, Illumina, Inc., GlaxoSmithKline plc, Hutchison China MediTech Limited и других отечественных и международных игроков. Аналитики DBMR понимают конкурентные преимущества и предоставляют конкурентный анализ для каждого конкурента отдельно.

Стратегические инициативы участников рынка, вкладывающих капитал в исследования нейроэндокринных опухолей, сокращают разрыв между лихорадкой денге и ее лечением.

Например,

  • В августе 2020 года компания F. Hoffmann-La Roche Ltd объявила, что Европейская комиссия предоставила приоритетное одобрение на регистрацию препарата Rozlytrek для лечения взрослых и детей в возрасте 12 лет, страдающих прогрессирующим немелкоклеточным раком легких. Полученное одобрение основано на кумулятивном анализе клинических испытаний II фазы STARTRK-2. Полученное компанией одобрение приведет к росту исследовательских партнерств, своевременному лечению пациентов и росту доходов. Это продемонстрирует положительный рост на рынке.

Сотрудничество, совместные предприятия и другие стратегии участников рынка расширяют возможности компании на рынке нейроэндокринных опухолей, что также дает организациям возможность улучшить свое предложение продуктов для лечения нейроэндокринных опухолей.

 

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of THE EUROPE Neuroendocrine tumors market
    4. Currency and pricing
    5. LIMITATIONs
    6. MARKETS COVERED
  2. EUROPE Neuroendocrine tumors market: SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. DBMR TRIPOD DATA VALIDATION MODEL
    5. primary interviews with key opinion leaders
    6. MULTIVARIATE MODELLING
    7. classification LIFELINE CURVE
    8. DBMR MARKET POSITION GRID
    9. vendor share analysis
    10. MARKET end user COVERAGE GRID
    11. secondary sourcEs
    12. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
  5. Pipeline analysis
  6. Pricing Analysis
  7. EUROPE NEUROENDOCRINE TUMORS MARKET: REGULATIONS
    1. REGULATORY PROCEDURE IN THE U.S.
    2. REGULATORY PROCEDURE IN CANADA
    3. REGULATORY PROCEDURE IN EUROPE
    4. REGULATORY PROCEDURE IN CHINA
    5. REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
  8. COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
    1. MONOCLONAL ANTIBODY
    2. POLYCLONAL ANTIBODY
  9. Market Overview
    1. drivers
      1. Increased incidence of neuroendocrine tumor cases
      2. Technological advanceMENT for THE detection of neuroendocrine tumors
      3. Growth in the Number of Private Diagnostic Centers and Treatment Providers
      4. Presence of targeted treatment options
      5. Favorable reimbursement policies
    2. RESTRAINTS
      1. High Capital Investments & Low Benefit-Cost Ratio for biomarkers and orphan drugs
      2. Lack of awareness among the population
      3. Unmet needs and access to medical resources in several regions
      4. High cost of Diagnosis
    3. opportunities
      1. Increased Government initiatives
      2. Emerging therapies & development in treatment
      3. Rising collaborations among the market players
    4. challenges
      1. Side effects associated with treatments
      2. Stringent government regulations for THE development OF neuroendocrine tumor drugs
  10. Impact of COVID 19 on Europe Neuroendocrine tumors market
    1. Price Impact
    2. Impact of Demand
    3. Impact on supply chain:
    4. Strategic Decisions:
    5. CONCLUSION:
  11. Europe neuroendocrine tumors market, BY Classification
    1. overview
    2. non-functional net
    3. Funtional NET
  12. Europe neuroendocrine tumors market, BY site
    1. overview
    2. gastrointestinal tract (GI)
    3. lungs
    4. pancreas
  13. Europe neuroendocrine tumors market, BY GRADE
    1. overview
    2. Grade 2 (Intermediate-Grade Tumor)
    3. grade 3 (high-grade tumor)
    4. grade 1( low-grade tumor)
  14. Europe neuroendocrine tumors market, BY type
    1. overview
    2. DIAGNOSIS
      1. Blood Test
      2. imaging test
        1. CTSCAN
        2. MRI
        3. OTHERS
      3. biopsy
      4. Urine test
      5. Others
    3. treatment
      1. somatostatin analogs
        1. OCTREOTIDE
        2. LANREOTIDE
      2. TARGETED THERAPY
        1. EVEROLIMUS
        2. SUNITINIB
        3. OTHERS
      3. RADIATION THERAPY
        1. EXTERNAL-BEAM RADIATION
        2. INTERNAL-BEAM RADIATION
      4. surgery
        1. CHOLECYSTECTOMY
        2. OTHERS
      5. LIVER-DIRECTED TREATMENT
        1. RADIO FREQUENCY ABLATION (RFA)
        2. HEPATIC ARTERY EMBOLIZATION
        3. RADIOEMBOLIZATION
      6. Peptide Receptor Radionuclide Therapy (PRRT)/ Lutathera
  15. Europe neuroendocrine tumors market, BY ROUTE OF ADMINISTRATION
    1. overview
    2. oral
      1. tablets
      2. pills
      3. others
    3. parenteral
      1. subcutaneous
      2. intramuscular
      3. others
  16. Europe neuroendocrine tumors market, BY End User
    1. overview
    2. Hospitals
    3. speciality clinics
    4. radiation centers
    5. home healthcare
    6. others
  17. Europe neuroendocrine tumors market, BY Distribution Channel
    1. overview
    2. direct tender
    3. hospital pharmacy
    4. retail sales
    5. online pharmacy
    6. others
  18. EUROPE Neuroendocrine tumors market, by Geography
    1. EUROPE
      1. germany
      2. france
      3. U.K.
      4. ITALY
      5. Russia
      6. spain
      7. SWITZERLAND
      8. NETHERLANds
      9. TURKEY
      10. IRELAND
      11. POLAND
      12. AUSTRIA
      13. NORWAY
      14. HUNGARY
      15. LITHUANIA
      16. REST OF EUROPE
  19. Europe Neuroendocrine tumors market: COMPANY landscape
    1. company share analysis: Europe
  20. SWOT
  21. company profiles
    1. F. HOFFMANN-LA ROCHE LTD
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. BRISTOL-MYERS SQUIBB COMPANY
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    3. VIATRIS INC.
      1. COMPANY SNAPSHOT
      2. Company share analysis
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. THERMO FISHER SCIENTIFIC INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    5. NOVARTIS AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    6. REGENERON PHARMACEUTICALS, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    7. ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    8. BIONANO GENOMICS
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    9. BIOSYNTHEMA INC.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    10. CALLISTOPHARMA
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    11. ELI LILLY AND COMPANY
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. EXACT SCIENCES CORPORATION
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. GLAXOSMITHKLINE PLC
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    14. HUTCHISON CHINA MEDITECH LIMITED
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    15. IPSEN PHARMA
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    16. ILLUMINA, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    17. LUPIN
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    18. MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. PFIZER INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    20. SUN PHARMACEUTICAL INDUSTRIES LTD.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    21. TEVA PHARMACEUTICAL INDUSTRIES LTD.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
  22. questionnaire
  23. related reports

Список таблиц

TABLE 1 Europe Neuroendocrine tumors market, Pipeline Analysis

TABLE 2 Sales Data of oncology market for 2019/2020

TABLE 3 Europe Neuroendocrine tumors market, By Classification 2019-2028(USD Million)

TABLE 4 Europe Non-Functional NET in Neuroendocrine tumors market, By Classification 2019-2027 (USD Million)

TABLE 5 Europe Functional NET in Neuroendocrine tumors market, By Classification 2019-2027 (USD Million)

TABLE 6 Europe Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 7 Europe Gastrointestinal Tract (GI) in Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 8 Europe Lungs in Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 9 Europe Pancreas Neuroendocrine tumors market, By Site 2019-2028 (USD Million)

TABLE 10 Europe Neuroendocrine tumors market, By Grade 2019-2028 (USD Million)

TABLE 11 Europe Grade 2 (Intermediate-Grade Tumor) in Neuroendocrine tumors market, By Grade 2019-2028 (USD Million)

TABLE 12 Europe Grade 3 (High-Grade Tumor) in Neuroendocrine tumors market, By Grade 2019-2028 (USD Million)

TABLE 13 Europe Neuroendocrine tumors market, By grade 2019-2028 (USD Million)

TABLE 14 Europe Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 15 Europe Diagnosis in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 16 Europe Diagnosis in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 17 Europe Imaging Test in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 18 Europe Treatment Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 19 Europe Treatment in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 20 Europe somatostatin analogs in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 21 Europe Targeted Therapy in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 22 Europe Radiation Therapy in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 23 Europe surgery in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 24 Europe liver-directed treatment in Neuroendocrine tumors market, By Type 2019-2028 (USD Million)

TABLE 25 Europe Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 26 Europe Oral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 27 Europe Oral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 28 Europe Parenteral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 29 Europe Parenteral in Neuroendocrine tumors market, By Route of Administration, 2019-2028 (USD Million)

TABLE 30 Europe Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 31 Europe Hospitals in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 32 Europe Speciality Clinics in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 33 Europe Radiation Centers in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 34 Europe Others in radiotherapy market, By Region, 2018-2027 (USD Million)

TABLE 35 Europe Others in Neuroendocrine tumors market, By End User, 2019-2028 (USD Million)

TABLE 36 Europe Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 37 Europe Direct Tender in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 38 Europe Hospital Pharmacy in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 39 Europe Retail Sales in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 40 Europe Online Pharmacy in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 41 Europe Others in Neuroendocrine tumors market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 42 EUROPE Neuroendocrine tumors market, By Country, 2019-2028 (USD Million)

TABLE 43 EUROPEneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 44 Europeneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 45 EUROPEneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 46 EUROPEneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 47 EUROPEdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 48 Europeimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 49 EUROPEtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 50 EUROPEsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 51 EUROPEtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 52 EUROPEradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 53 EUROPEsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 54 EUROPEliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 55 EUROPEneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 56 EUROPEoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 57 EUROPEparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 58 EUROPEneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 59 EUROPE neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 60 GERMANY neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 61 Germany neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 62 GERMANY neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 63 GERMANYneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 64 GERMANYdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 65 GERMANY imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 66 GERMANY treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 67 GERMANY somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 68 GERMANY targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 69 GERMANY radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 70 GERMANY surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 71 GERMANYliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 72 GERMANYneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 73 GERMANYoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 74 GERMANYparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 75 GERMANYneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 76 GERMANY neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 77 FRANCE neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 78 France neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 79 FRANCE neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 80 FRANCE neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 81 France diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 82 France imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 83 FRANCEtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 84 FRANCEsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 85 FRANCEtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 86 FRANCEradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 87 FRANCEsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 88 FRANCEliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 89 FRANCEneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 90 FRANCEoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 91 FRANCEparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 92 FRANCEneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 93 FRANCE neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 94 U.K. neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 95 U.K. neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 96 U.K. neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 97 U.K. neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 98 U.K. diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 99 U.K. imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 100 U.K.treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 101 U.K.somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 102 U.K.targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 103 U.K.radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 104 U.K.surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 105 U.K.liver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 106 U.K.neuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 107 U.K.oral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 108 U.K.parenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 109 U.K.neuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 110 U.K. neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 111 ITALYneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 112 ITALYneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 113 ITALYneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 114 ITALYneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 115 ITALYdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 116 ITALYimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 117 ITALYtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 118 ITALYsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 119 ITALYtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 120 ITALYradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 121 ITALYsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 122 ITALYliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 123 ITALYneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 124 ITALYoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 125 ITALYparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 126 ITALYneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 127 ITALY neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 128 RUSSIA neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 129 RUSSIAneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 130 RUSSIAneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 131 RUSSIAneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 132 RUSSIAdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 133 RUSSIAimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 134 RUSSIAtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 135 RUSSIAsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 136 RUSSIAtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 137 RUSSIAradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 138 RUSSIAsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 139 RUSSIAliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 140 RUSSIAneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 141 RUSSIAoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 142 RUSSIAparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 143 RUSSIAneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 144 RUSSIA neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 145 SPAIN neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 146 SPAIN NEUROENDOCRINE TUMORS MARKET, By site, 2021-2028 (USD Million)

TABLE 147 SPAIN NEUROENDOCRINE TUMORS MARKET, By grade, 2021-2028 (USD Million)

TABLE 148 SPAIN NEUROENDOCRINE TUMORS MARKET, By Type, 2021-2028 (USD Million)

TABLE 149 SPAINdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 150 SPAINimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 151 SPAINtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 152 SPAINsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 153 SPAINtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 154 SPAINradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 155 SPAINsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 156 SPAINliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 157 SPAIN NEUROENDOCRINE TUMORS MARKET, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 158 SPAINoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 159 SPAINparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 160 SPAIN NEUROENDOCRINE TUMORS MARKET, By end user, 2021-2028 (USD Million)

TABLE 161 SPAIN neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 162 SWITZERLAND neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 163 SWITZERLAND neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 164 SWITZERLANDneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 165 SWITZERLANDneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 166 SWITZERLANDdiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 167 SWITZERLANDimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 168 SWITZERLANDtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 169 SWITZERLANDsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 170 SWITZERLANDtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 171 SWITZERLANDradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 172 SWITZERLANDsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 173 SWITZERLANDliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 174 SWITZERLANDneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 175 SWITZERLANDoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 176 SWITZERLANDparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 177 SWITZERLANDneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 178 SWITZERLAND neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 179 NETHERLANDs neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION )

TABLE 180 NETHERLANDs neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 181 NETHERLANDs neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 182 NETHERLANDs neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 183 NETHERLANDs diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 184 NETHERLANDs imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 185 NETHERLANDs treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 186 NETHERLANDs somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 187 NETHERLANDs targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 188 NETHERLANDs radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 189 NETHERLANDs surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 190 NETHERLANDs liver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 191 NETHERLANDs neuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 192 NETHERLANDs oral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 193 NETHERLANDs parenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 194 NETHERLANDs neuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 195 NETHERLANDs neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 196 Turkey neuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 197 Turkey neuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 198 Turkey neuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 199 Turkey neuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 200 Turkey diagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 201 Turkey imaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 202 Turkey treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 203 Turkey somatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 204 Turkey targeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 205 Turkey radiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 206 Turkey surgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 207 Turkey liver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 208 Turkey neuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 209 Turkey oral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 210 Turkey parenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 211 Turkey neuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 212 Turkey neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 213 Irelandneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 214 Irelandneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 215 Irelandneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 216 Irelandneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 217 Irelanddiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 218 Irelandimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 219 Irelandtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 220 Irelandsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 221 Irelandtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 222 Irelandradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 223 Irelandsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 224 Irelandliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 225 Irelandneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 226 Irelandoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 227 Irelandparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 228 Irelandneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 229 Ireland neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 230 Polandneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 231 Polandneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 232 Polandneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 233 Polandneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 234 Polanddiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 235 Polandimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 236 Polandtreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 237 Polandsomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 238 Polandtargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 239 Polandradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 240 Polandsurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 241 Polandliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 242 Polandneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 243 Polandoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 244 Polandparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 245 Polandneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 246 Poland neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 247 Austrianeuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 248 Austrianeuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 249 Austrianeuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 250 Austrianeuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 251 Austriadiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 252 Austriaimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 253 Austriatreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 254 Austriasomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 255 Austriatargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 256 Austriaradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 257 Austriasurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 258 Austrialiver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 259 Austrianeuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 260 Austriaoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 261 Austriaparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 262 Austrianeuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 263 Austria neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 264 Norwayneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 265 Norwayneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 266 Norwayneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 267 Norwayneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 268 Norwaydiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 269 Norwayimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 270 Norwaytreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 271 Norwaysomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 272 Norwaytargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 273 Norwayradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 274 Norwaysurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 275 Norwayliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 276 Norwayneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 277 Norwayoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 278 Norwayparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 279 Norwayneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 280 Norway neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 281 Hungaryneuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 282 Hungaryneuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 283 Hungaryneuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 284 Hungaryneuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 285 Hungarydiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 286 Hungaryimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 287 Hungarytreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 288 Hungarysomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 289 Hungarytargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 290 Hungaryradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 291 Hungarysurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 292 Hungaryliver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 293 Hungaryneuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 294 Hungaryoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 295 Hungaryparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 296 Hungaryneuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 297 Hungary neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 298 Lithuanianeuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

TABLE 299 Lithuanianeuroendocrine tumors market, By site, 2021-2028 (USD Million)

TABLE 300 Lithuanianeuroendocrine tumors market, By grade, 2021-2028 (USD Million)

TABLE 301 Lithuanianeuroendocrine tumors market, By Type, 2021-2028 (USD Million)

TABLE 302 Lithuaniadiagnosis in NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 303 Lithuaniaimaging test in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 304 Lithuaniatreatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 305 Lithuaniasomatostatin analogs in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 306 Lithuaniatargeted therapy in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 307 Lithuaniaradiation THERAPY in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 308 Lithuaniasurgery in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 309 Lithuanialiver directed treatment in neuroendocrine tumors market, By type, 2021-2028 (USD Million)

TABLE 310 Lithuanianeuroendocrine tumors market, By ROUTE OF ADMINISTRATION , 2021-2028 (USD Million)

TABLE 311 Lithuaniaoral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 312 Lithuaniaparenteral in neuroendocrine tumors market, By ROUTE OF ADMINISTRATION, 2021-2028 (USD Million)

TABLE 313 Lithuanianeuroendocrine tumors market, By end user, 2021-2028 (USD Million)

TABLE 314 Lithuania neuroendocrine tumors market, By distribution channel, 2021-2028 (USD Million)

TABLE 315 REST OF EUROPE Neuroendocrine tumors market, By classification 2019-2028 (USD Million)

TABLE 316 Lithuanianeuroendocrine tumors market, By classification, 2021-2028 (USD MILLION)

Список рисунков

FIGURE 1 EUROPE Neuroendocrine tumors market: segmentation

FIGURE 2 EUROPE Neuroendocrine tumors market: data triangulation

FIGURE 3 EUROPE NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE Neuroendocrine tumors market: Europe VS REGIONAL ANALYSIS

FIGURE 5 EUROPE Neuroendocrine tumors market: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE Neuroendocrine tumors market: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE Neuroendocrine tumors market: DBMR MARKET POSITION GRID

FIGURE 8 Europe neuroendocrine tumors market: vendor share analysis

FIGURE 9 Europe neuroendocrine tumors market: MARKET end user COVERAGE GRID

FIGURE 10 EUROPE Neuroendocrine tumors market: SEGMENTATION

FIGURE 11 increased awareness of neuroendocrine tumors cases is expected to drive the EUROPE Neuroendocrine tumors market in the forecast period of 2021 to 2028

FIGURE 12 non-funtional net segment is expected to account for the largest share of the Europe Neuroendocrine tumors market in 2021 & 2028

FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016

FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.

FIGURE 15 Europe neuroendocrine tumors market: BY classification, 2020

FIGURE 16 EUROPE neuroendocrine tumors market, BY classification, 2020-2028 (USD MILLION)

FIGURE 17 EUROPE neuroendocrine tumors market: BY classification, CAGR (2021-2028)

FIGURE 18 EUROPE neuroendocrine tumors market: BY classification, LIFELINE CURVE

FIGURE 19 Europe neuroendocrine tumors market: BY site, 2020

FIGURE 20 EUROPE neuroendocrine tumors market, BY site, 2020-2028 (USD MILLION)

FIGURE 21 EUROPE neuroendocrine tumors market: BY site, CAGR (2021-2028)

FIGURE 22 EUROPE neuroendocrine tumors market: BY site, LIFELINE CURVE

FIGURE 23 Europe neuroendocrine tumors market: BY grade, 2020

FIGURE 24 EUROPE neuroendocrine tumors market, BY grade, 2020-2028 (USD MILLION)

FIGURE 25 EUROPE neuroendocrine tumors market: BY grade, CAGR (2021-2028)

FIGURE 26 EUROPE neuroendocrine tumors market: BY grade, LIFELINE CURVE

FIGURE 27 Europe neuroendocrine tumors market: BY type, 2020

FIGURE 28 EUROPE neuroendocrine tumors market, BY type, 2020-2028 (USD MILLION)

FIGURE 29 EUROPE neuroendocrine tumors market: BY type, CAGR (2021-2028)

FIGURE 30 EUROPE neuroendocrine tumors market: BY type, LIFELINE CURVE

FIGURE 31 Europe neuroendocrine tumors market: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 EUROPE neuroendocrine tumors market, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 33 EUROPE neuroendocrine tumors market: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 EUROPE neuroendocrine tumors market: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE

FIGURE 35 Europe neuroendocrine tumors market: BY end user, 2020

FIGURE 36 EUROPE neuroendocrine tumors market, BY end user, 2020-2028 (USD MILLION)

FIGURE 37 EUROPE neuroendocrine tumors market: BY end user, CAGR (2021-2028)

FIGURE 38 EUROPE neuroendocrine tumors market: BY end user, LIFELINE CURVE

FIGURE 39 Europe neuroendocrine tumors market: BY distribution channel, 2020

FIGURE 40 EUROPE neuroendocrine tumors market, BY distribution channel, 2020-2028 (USD MILLION)

FIGURE 41 EUROPE neuroendocrine tumors market: BY distribution channel, CAGR (2021-2028)

FIGURE 42 EUROPE neuroendocrine tumors market: BY distribution channel, LIFELINE CURVE

FIGURE 43 EUROPE neuroendocrine tumors market: SNAPSHOT (2020)

FIGURE 44 EUROPE neuroendocrine tumors market: BY COUNTRY (2020)

FIGURE 45 EUROPE neuroendocrine tumors market: BY COUNTRY (2021 & 2028)

FIGURE 46 EUROPE neuroendocrine tumors market: BY COUNTRY (2021 & 2028)

FIGURE 47 EUROPE neuroendocrine tumors market: BY classification (2021-2028)

FIGURE 48 Europe neuroendocrine tumors market: company share 2020 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Просмотр связанных страниц

Banner